Product image of Granisetron Crescent Pharma (Granisetron) supplied by GNH India

Granisetron Crescent Pharma

Active Ingredient:
Granisetron
Origin:
EU

Granisetron Crescent Pharma (Granisetron)

Granisetron Crescent Pharma is an oral formulation containing the active ingredient granisetron. It is a prescription‑only 5‑HT3 receptor antagonist marketed in the European Union. The product is used to manage nausea and vomiting associated with chemotherapy and surgery, acting by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract.

Manufacturer / TM Owner

Crescent Pharma Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Crescent Pharma is indicated for the prevention and treatment of nausea and vomiting in specific clinical settings.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV).
  • Treatment of acute CINV episodes.
  • Prevention of postoperative nausea and vomiting (PONV).
  • Adjunct therapy for radiation‑induced nausea when chemotherapy is also administered.
  • Use in patients who have not responded adequately to other antiemetics.

Side Effects

Granisetron Crescent Pharma may cause a range of side effects, most of which are mild and transient.

Common

  • Headache
  • Constipation
  • Fatigue or drowsiness
  • Dizziness
  • Transient mild abdominal discomfort

Serious

  • Severe allergic reaction (rash, itching, swelling, difficulty breathing)
  • Cardiac arrhythmia or prolonged QT interval (rare)
  • Severe constipation leading to bowel obstruction
  • Persistent or worsening dizziness with visual disturbances

Precautions & Warnings

When prescribing Granisetron Crescent Pharma, clinicians should consider several safety factors.

  • Assess patient history for cardiac conduction disorders or prolonged QT interval.
  • Use caution in patients with severe hepatic impairment, as metabolism may be reduced.
  • Monitor for signs of hypersensitivity, especially after the first dose.
  • Evaluate the need for dose adjustment in elderly patients.
  • Discuss potential constipation and advise patients to maintain adequate hydration and fiber intake.
  • Consider alternative antiemetics if the patient is taking other QT‑prolonging drugs.

Avoid Interactions

Granisetron Crescent Pharma can interact with other medications, influencing efficacy or safety.

Avoid

  • Other 5‑HT3 antagonists used concurrently, which may increase risk of cardiac effects.
  • Drugs known to significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).

Use with caution

  • Anticholinergic agents that may exacerbate constipation.
  • CYP3A4 inhibitors or inducers, although granisetron metabolism is limited, monitoring is advised.
  • Opioids, as combined use may increase the risk of dizziness or sedation.
  • Diuretics, due to potential electrolyte shifts affecting cardiac repolarization.

Frequently Asked Questions

Granisetron selectively blocks serotonin 5‑HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing the stimulus for nausea and vomiting.

No. Granisetron Crescent Pharma is a prescription‑only medication in the European Union.

Granisetron is not typically indicated for motion sickness; it is primarily used for chemotherapy‑ and postoperative‑induced nausea and vomiting.

The medication is usually administered orally before chemotherapy, following the dosing schedule prescribed by the treating physician.

Common side effects include headache, constipation, fatigue, dizziness, and mild abdominal discomfort.

Serious reactions can include severe allergic responses, cardiac arrhythmias or QT prolongation, and severe constipation that may lead to bowel obstruction.

Patients with known QT prolongation or other cardiac conduction disorders should be evaluated carefully, and alternative antiemetics may be considered.

Concurrent use with other 5‑HT3 antagonists should be avoided, and combinations with drugs that prolong QT interval require close monitoring.

The pregnancy safety category for Granisetron Crescent Pharma is not established; clinicians should weigh potential benefits against risks and consider alternative therapies.

Patients should contact their healthcare provider for guidance; generally, they should not double the dose and should follow the prescribed schedule.

Granisetron is primarily metabolized in the liver and excreted via the kidneys; dose adjustments may be needed in severe hepatic or renal impairment.

Food may slightly delay absorption but does not significantly affect overall efficacy; the medication can be taken with or without meals as directed.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT